Inactive

Modification P00008 SPE2D220D0096 has been issued to invoke option year 4 effective August 27, 2024 through August 26, 2025. All other terms and conditions remain unchanged.

Inactive

Amendment 0007 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets extends the closing date until April 30, 2020 at 3:00 PM DST. Submission of offers via DIBBS submittial. Amendment 0006 supercedes Amendme... Amendment 0007 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets extends the closing date until April 30, 2020 at 3:00 PM DST. Submission of offers via DIBBS submittial. Amendment 0006 supercedes Amendment 0005 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets is to allow only DIBBS submittial of offers. Any other submittial of offers is not acceptable. Closing date has been extended until April 23, 2020 at 3:00 PM DST. Amendment 0005 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets extends the closing date until April 23, 2020 at 3:00 PM DST and to update email submissions of offers. Amendment 0004 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets closing date extended until April 16, 2020 at 3:00 PM DST to allow email submissions of offers. Amendment 0003 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets closing date extended until April 09, 2020 at 3:00 PM DST. Amendment 0002 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets to incoproate three (3) DFARS clauses into solicitation. Amendment 0001 SPE2D2-20-R-0061 Rabeprazole Sodium DR Tablets to incorporate two (2) DFARS clauses into solicitation. Solicitation for Rabeprazole Sodium DR Tablets SPE2D2-20-R-0061.